Literature DB >> 18562136

In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors.

Roula Konsoula1, Mira Jung.   

Abstract

Histone deacetylase inhibitors (HDACIs) are emerging as a new class of therapeutic agents with potent antitumor activities in a broad spectrum of human cancers. In this study, the in vitro plasma stability, permeability, solubility, and lipophilicity (log D) of two mercaptoacetamide-based HDACIs (coded as W2 and S2) were evaluated and compared to Vorinostat (SAHA). The results demonstrated that the compounds manifested high solubility in HCl (pH 1.2) but lower in PBS (pH 7.4) than SAHA. Moreover, mercaptoacetamide-based HDACIs exhibited higher lipophilicity values compared to SAHA. The permeability of these compounds was evaluated using the Caco-2 cell monolayer as a model of the intestinal mucosa. The Caco-2 studies revealed that the compounds S2 and W2 are highly permeable with apparent permeability coefficients (P(app)) in the apical to basolateral direction of 7.33 x 10(-6) and 15.0 x 10(-6)cm/s, respectively. The in vitro stability was determined in human, mouse, porcine and rat plasma. Data showed that the compound W2 is more stable in human and rat plasma and the S2 is more stable in all plasma species than SAHA. Taken together, these results indicate that the mercaptoacetamide-based HDACIs possess favorable solubility, lipophilicity, permeability and plasma stability features.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562136      PMCID: PMC2565275          DOI: 10.1016/j.ijpharm.2008.05.001

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  35 in total

1.  Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.

Authors:  S Pikul; N E Ohler; G Ciszewski; M C Laufersweiler; N G Almstead; B De; M G Natchus; L C Hsieh; M J Janusz; S X Peng; T M Branch; S L King; Y O Taiwo; G E Mieling
Journal:  J Med Chem       Date:  2001-08-02       Impact factor: 7.446

2.  Rate-limited steps of human oral absorption and QSAR studies.

Authors:  Yuan H Zhao; Michael H Abraham; Joelle Le; Anne Hersey; Chris N Luscombe; Gordon Beck; Brad Sherborne; Ian Cooper
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

Review 3.  Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques.

Authors:  A Avdeef; B Testa
Journal:  Cell Mol Life Sci       Date:  2002-10       Impact factor: 9.261

4.  FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.

Authors:  Ryohei Furumai; Akihisa Matsuyama; Nobuyuki Kobashi; Kun-Hyung Lee; Makoto Nishiyama; Hidenori Nakajima; Akito Tanaka; Yasuhiko Komatsu; Norikazu Nishino; Minoru Yoshida; Sueharu Horinouchi
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

Review 5.  Histone deacetylases and cancer: causes and therapies.

Authors:  P Marks; R A Rifkind; V M Richon; R Breslow; T Miller; W K Kelly
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

6.  Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.

Authors:  M R Michaelides; J F Dellaria; J Gong; J H Holms; J J Bouska; J Stacey; C K Wada; H R Heyman; M L Curtin; Y Guo; C L Goodfellow; I B Elmore; D H Albert; T J Magoc; P A Marcotte; D W Morgan; S K Davidsen
Journal:  Bioorg Med Chem Lett       Date:  2001-06-18       Impact factor: 2.823

Review 7.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.

Authors:  Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

8.  Comparison of in vitro activities of biotransformation enzymes in pig, cattle, goat and sheep.

Authors:  B Szotáková; V Baliharová; J Lamka; E Nozinová; V Wsól; J Velík; M Machala; J Neca; P Soucek; S Susová; L Skálová
Journal:  Res Vet Sci       Date:  2004-02       Impact factor: 2.534

9.  Thiol-based SAHA analogues as potent histone deacetylase inhibitors.

Authors:  Takayoshi Suzuki; Akiyasu Kouketsu; Azusa Matsuura; Arihiro Kohara; Shin-Ichi Ninomiya; Kohfuku Kohda; Naoki Miyata
Journal:  Bioorg Med Chem Lett       Date:  2004-06-21       Impact factor: 2.823

Review 10.  Histone deacetylase inhibitors open new doors in cancer therapy.

Authors:  Fiona McLaughlin; Nicholas B La Thangue
Journal:  Biochem Pharmacol       Date:  2004-09-15       Impact factor: 5.858

View more
  25 in total

1.  Exposure time versus cytotoxicity for anticancer agents.

Authors:  David M Evans; Jianwen Fang; Thomas Silvers; Rene Delosh; Julie Laudeman; Chad Ogle; Russell Reinhart; Michael Selby; Lori Bowles; John Connelly; Erik Harris; Julia Krushkal; Larry Rubinstein; James H Doroshow; Beverly A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  2019-05-17       Impact factor: 3.333

2.  Assessment and modulation of phillyrin absorption by P-gp using Caco-2 cells and MDR1-MDCKII cells.

Authors:  Yun-Xia Li; Liang-Hong Ye; Xue-Hua Jiang; Cheng Peng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-02-20       Impact factor: 2.441

3.  Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development.

Authors:  Kelly A Bachovchin; Amrita Sharma; Seema Bag; Dana M Klug; Katherine M Schneider; Baljinder Singh; Hitesh B Jalani; Melissa J Buskes; Naimee Mehta; Scott Tanghe; Jeremiah D Momper; Richard J Sciotti; Ana Rodriguez; Kojo Mensa-Wilmot; Michael P Pollastri; Lori Ferrins
Journal:  J Med Chem       Date:  2019-01-10       Impact factor: 7.446

4.  Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(DL-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine.

Authors:  Elham A Mohamed; Yunqi Zhao; Mahasen M Meshali; Connie M Remsberg; Thanaa M Borg; Abdel Monem M Foda; Jody K Takemoto; Casey L Sayre; Stephanie E Martinez; Neal M Davies; M Laird Forrest
Journal:  J Pharm Sci       Date:  2012-07-17       Impact factor: 3.534

5.  Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells.

Authors:  Tuan Hiep Tran; Thiruganesh Ramasamy; Duy Hieu Truong; Beom Soo Shin; Han-Gon Choi; Chul Soon Yong; Jong Oh Kim
Journal:  Pharm Res       Date:  2014-02-22       Impact factor: 4.200

6.  Functional Roles of Acetylated Histone Marks at Mouse Meiotic Recombination Hot Spots.

Authors:  Irina V Getun; Zhen Wu; Mohammad Fallahi; Souad Ouizem; Qin Liu; Weimin Li; Roberta Costi; William R Roush; John L Cleveland; Philippe R J Bois
Journal:  Mol Cell Biol       Date:  2017-01-19       Impact factor: 4.272

7.  Assessment and modulation of forsythiaside absorption with MDCKII cells and validation with in situ intestinal experiment.

Authors:  Yun-Xia Li; Ruo-Qi Zhang; Cheng Peng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-03-20       Impact factor: 2.441

8.  Structure-Activity Relationships of [des-Arg7]Dynorphin A Analogues at the κ Opioid Receptor.

Authors:  Cyf N Ramos-Colon; Yeon Sun Lee; Michael Remesic; Sara M Hall; Justin LaVigne; Peg Davis; Alexander J Sandweiss; Mary I McIntosh; Jessica Hanson; Tally M Largent-Milnes; Todd W Vanderah; John Streicher; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2016-11-08       Impact factor: 7.446

9.  Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease.

Authors:  You Me Sung; Taehee Lee; Hyejin Yoon; Amanda Marie DiBattista; Jung Min Song; Yoojin Sohn; Emily Isabella Moffat; R Scott Turner; Mira Jung; Jungsu Kim; Hyang-Sook Hoe
Journal:  Exp Neurol       Date:  2012-10-11       Impact factor: 5.330

10.  Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors.

Authors:  Zacharoula Konsoula; Hong Cao; Alfredo Velena; Mira Jung
Journal:  Mol Cancer Ther       Date:  2009-09-29       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.